Nobel Prize in Medicine Awarded to 3 Scientists for Oxygen Research

STOCKHOLM — The 2019 Nobel Prize for Physiology or Medicine has been awarded to scientists William G. Kaelin, Jr, Peter J. Ratcliffe and Gregg L. Semenza. They received the award jointly for their discoveries of “how cells sense and adapt to oxygen availability,” the Nobel Committee announced Monday. Two of the scientists, Kaelin and Semenza, are U.S.-based, at Harvard University and Johns Hopkins respectively. The other scientist, Ratcliffe, is based at the Francis Crick Institute in London. BREAKING NEWS:The 2019 #NobelPrize in Physiology or Medicine has been awarded jointly to William G. Kaelin Jr, Sir Peter J. Ratcliffe and Gregg L. Semenza “for their discoveries of how cells sense and adapt to oxygen availability.” pic.twitter.com/6m2LJclOoL — The Nobel Prize (@NobelPrize) October 7, 2019 It is the 110th prize in the category that has been awarded since 1901. The Karolinska Institutet said in a statement the trio should share equally the 9 million kronor ($918,000) cash award. The discoveries made by the three men “have fundamental importance for physiology and have paved the way for promising new strategies to fight anemia, cancer and many other diseases,” the Committee said.
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized nobel prize Source Type: news

Related Links:

This study was designed to evaluate the efficacy and safety of apatinib, a novel tyrosine kinase inhibitor targeting tumor angiogenesis, as second-line treatment in recurrent or advanced cervical cancer patients. Twenty patients who failed cisplatin/paclitaxel ± bevacizumab treatment received a 4-week cycle of apatinib, with a daily dosage of 500 mg or 250 mg. The follow-up period ranged from 5.9 to 21.3 months (median, 14.0 months). None of the patients achieved a complete response (CR). Nevertheless, a partial response (PR), stable disease (SD) an d progressive disease (PD) were observed i...
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
Tumor-treating fields (TTFields) is a non-invasive physical modality of cancer therapy that applies low-intensity, intermediate frequency, alternating electric fields to a tumor. Interference with mitosis was the first mechanism describing the effects of TTFields on cancer cells, however, TTFields was shown to not only reduce the rejoining of radiation-induced DNA double-strand breaks (DSBs), but to also induce DNA DSBs. The mechanism(s) by which TTFields generates DNA DSBs is related to the generation of replication stress including reduced expression of the DNA replication complex genes MCM6 and MCM10 and the Fanconi's Anemia pathway genes.
Source: Translational Research - Category: Research Authors: Source Type: research
Publication date: Available online 19 October 2019Source: Biochimica et Biophysica Acta (BBA) - Molecular Basis of DiseaseAuthor(s): Brittany Haynes, Ambikai Gajan, Pratima Nangia-Makker, Malathy P. ShekharAbstractTriple negative breast cancer (TNBC) is an aggressive breast cancer subtype with few therapy options besides chemotherapy. Although platinum-based drugs have shown initial activity in BRCA1-mutated TNBCs, chemoresistance remains a challenge. Here we show that RAD6B (UBE2B), a principal mediator of translesion synthesis (TLS), is overexpressed in BRCA1 wild-type and mutant TNBCs, and RAD6B overexpression correlate...
Source: Biochimica et Biophysica Acta (BBA) Molecular Basis of Disease - Category: Molecular Biology Source Type: research
AbstractThere is still uncertainty about the optimal usage of thrombolysis for acute pulmonary embolisms (PEs), leading to a widely varying usage in the real world. The COMMAND VTE Registry is a multicenter retrospective registry enrolling consecutive patients with acute symptomatic venous thromboembolisms (VTEs) in Japan. The present study population consisted of 1549 patients with PEs treated with tissue plasminogen activator (t-PA) thrombolysis (N  = 180, 12%) or without thrombolysis (N = 1369). Thrombolysis with t-PA was implemented in 33% of patients with severe PEs, and 9.2% of patients wi...
Source: Journal of Thrombosis and Thrombolysis - Category: Hematology Source Type: research
Acute myeloid leukemia (AML) represents 80% of adult leukemias and 15–20% of childhood leukemias. AML are characterized by the presence of 20% blasts or more in the bone marrow, or defining cytogenetic abnormalities. Laboratory diagnoses of myelodysplastic syndromes (MDS) depend on morphological changes based on dysplasia in peripheral blood and bone marrow, including peripheral blood smears, bone marrow aspirate smears, and bone marrow biopsies. As leukemic cells are not functional, the patient develops anemia, neutropenia, and thrombocytopenia, leading to fatigue, recurrent infections, and hemorrhage. The genetic b...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsThe exposure –response analysis suggested that intermittent 7-day veliparib 120 mg BID dosing in a 21-day cycle provided additional efficacy without meaningfully impacting the safety and tolerability when co-administered with carboplatin and paclitaxel in patients with BRCA-deficient breast cancer. A higher d ose of veliparib is unlikely to provide greater benefit in this combination in patients with BRCA-deficient recurrent or metastatic breast cancer.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
Conditions:   Aplastic Anemia;   Paroxysmal Nocturnal Hemoglobinuria Interventions:   Other: symptom questionnaire;   Other: recording of vital signs;   Other: European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ)-C30 questionnaire;   Other: interview Sponsors:   University Hospital, Basel, Switzerland;   ProPatient foundation of the University Hospital Basel;   Novartis Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
In this study, in vitro evaluation of anti-tumor and anti-angiogenic activities of NS, MTX, or their mixture in different concentrations using liver hepatocellular carcinoma and endothelial cells were performed. The protective effects of NS on normal hepatic and kidney cells against the risks of MTX treatment was also tested in vitro. Moreover, for in vivo evaluation, male Wistar rats were treated with MTX or a combination of MTX and NS. Hematological and serological, biochemical, functional, and histopathological studies were performed. The results showed that the low concentration of NS enhanced the anti-tumor and anti-a...
Source: Comparative Clinical Pathology - Category: Pathology Source Type: research
Conclusion: Data from our study suggest nivolumab is well-tolerated and effective in Indian patients with recurrent advanced NSCLC after failure of the multiple first lines of platinum-based combination chemotherapy.
Source: Indian Journal of Cancer - Category: Cancer & Oncology Authors: Source Type: research
Triple-negative breast cancer (TNBC) is associated with worse prognosis, with limited treatment regiments available and higher mortality rate. Immune checkpoint inhibitors targeting programmed cell death-1 (PD-1) or programmed cell death-ligand 1 (PD-L1) showed great potentials in treating malignancies and may serve as potential therapies for TNBC. This systematic review aims to evaluate the efficacy and safety profiles of PD-1/PD-L1 inhibitors in the treatment of TNBC. Literature search was performed via PubMed, EBSCOhost, Scopus, and CENTRAL databases, selecting studies which evaluated the use of anti-PD-1/PD-L1 for TNBC...
Source: Oncology Reviews - Category: Cancer & Oncology Source Type: research
More News: Anemia | Cancer | Cancer & Oncology | Harvard | Health | Physiology